Moclobemide exerts anti-inflammatory effect in lipopolysaccharide-activated primary mixed glial cell culture.
An increasing body of evidence indicates that glial activation and neuroinflammation play an important role in the pathogenesis of psychiatric and neurodegenerative diseases. Activated glial cells secrete various cytokines that influence neurotransmission, hypothalamus-pituitary-adrenal axis activity, neuronal plasticity and neurogenesis. It has been suggested that alterations in cytokine networks are involved in the mechanism of action of antidepressant drugs. Until now, only a few studies demonstrated that some tricyclic antidepressants and selective serotonin reuptake inhibitors reduced production of pro-inflammatory cytokines in brain glia cells. We have investigated for the first time whether the antidepressant, moclobemide (a reversible selective inhibitor of monoamine oxidase-A) has an influence on pro-inflammatory cytokines [interleukin (IL)-1β and tumor necrosis factor (TNF)-α] and anti-inflammatory cytokine (IL-10) in primary rat mixed glial cell cultures stimulated by lipopolysaccharide (LPS). Our results showed that moclobemide used in a wide range of concentrations diminished LPS-stimulated IL-1β and TNF-α mRNAs expression in cellular extracts and remarkably reduced the levels of both pro-inflammatory cytokines in culture medium. In opposite to this, the drug had no influence on IL-10 mRNA and slightly reduced IL-10 concentration. Moreover, moclobemide decreased LPS-stimulated translocation of NFκB p65 subunit into cellular nuclei. These results suggest that moclobemide exerts anti-inflammatory effect in the central nervous system because it affects the balance between pro- and anti-inflammatory cytokines (IL-1β, TNF-α/IL-10) in primary mixed glial cell cultures.
Bielecka
A M
AM
Department of Pharmacology, Medical University of Silesia, Medyków 18, 40-752, Katowice, Poland. amb2@vp.pl
Paul-Samojedny
M
M
Obuchowicz
E
E
D021581:Active Transport, Cell Nucleus; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology*; D000928:Antidepressive Agents / Q000494:pharmacology; D002467:Cell Nucleus / Q000378:metabolism; D002478:Cells, Cultured; D016753:Interleukin-10 / Q000096:biosynthesis; D053583:Interleukin-1beta / Q000096:biosynthesis; D008070:Lipopolysaccharides / Q000494:pharmacology*; D020912:Moclobemide / Q000494:pharmacology*; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology; D009457:Neuroglia / Q000187:drug effects* / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D051996:Transcription Factor RelA / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis
D000893:Anti-Inflammatory Agents; D000928:Antidepressive Agents; D053583:Interleukin-1beta; D008070:Lipopolysaccharides; D008996:Monoamine Oxidase Inhibitors; D051996:Transcription Factor RelA; D014409:Tumor Necrosis Factor-alpha; D016753:Interleukin-10; D020912:Moclobemide
Glia. 2006 Apr 1;53(5):551-6
16374779
Br J Pharmacol. 2002 Feb;135(3):713-20
11834619
Free Radic Biol Med. 2007 Apr 1;42(7):945-54
17349923
Med Hypotheses. 1991 Aug;35(4):298-306
1943879
Curr Opin Investig Drugs. 2009 Jul;10(7):664-71
19579172
Neuropharmacology. 2000 Aug 23;39(11):2067-74
10963750
Mol Immunol. 2009 Dec;47(2-3):205-14
19850345
Environ Health Perspect. 1983 Sep;51:23-5
6315363
Annu Rev Biochem. 2002;71:635-700
12045108
J Pharmacol Exp Ther. 2006 Oct;319(1):44-52
16807359
Front Neuroendocrinol. 2009 Jan;30(1):30-45
19017533
Adv Exp Med Biol. 1999;461:25-46
10442165
Curr Med Chem. 2004 Aug;11(15):2033-43
15279566
Eur J Neurosci. 2005 May;21(9):2347-60
15932594
J Affect Disord. 2000 Apr;58(1):69-74
10760560
Free Radic Biol Med. 2008 Nov 15;45(10):1493-9
18822370
J Biol Chem. 2004 Dec 24;279(52):54470-8
15471874
Brain Res. 2007 Mar 23;1138:30-8
17274964
Psychopharmacology (Berl). 1992;106 Suppl:S134-6
1546129
Anal Biochem. 1976 May 7;72:248-54
942051
J Psychiatr Res. 1998 Mar-Apr;32(2):111-5
9694007
J Neural Transm Suppl. 1987;25:15-25
3480938
J Biol Chem. 2006 Jul 28;281(30):21362-21368
16720574
J Neural Transm (Vienna). 2003 Dec;110(12):1413-36
14666413
Neuroimmunomodulation. 2007;14(3-4):168-74
18073510
Br J Pharmacol. 2006 Jul;148(5):587-98
16702990
Brain Res Dev Brain Res. 2003 Mar 14;141(1-2):25-32
12644245
Prog Neuropsychopharmacol Biol Psychiatry. 2005 Feb;29(2):201-17
15694227
Int J Neuropsychopharmacol. 2008 Feb;11(1):111-7
17445357
Int J Neuropsychopharmacol. 2006 Feb;9(1):27-35
15963243
Psychopharmacology (Berl). 1992;106 Suppl:S56-61
1546142
Neuropharmacology. 2008 Oct;55(5):826-34
18639562
Int J Neuropsychopharmacol. 2002 Dec;5(4):401-12
12466038
J Pharmacol Sci. 2007 May;104(1):61-72
17510525
J Pharmacol Exp Ther. 1989 Jan;248(1):400-14
2783611
J Neurochem. 1999 Apr;72(4):1466-71
10098850
Neuroscience. 2007 Jul 29;147(4):867-83
17459594
Metab Brain Dis. 2009 Mar;24(1):27-53
19085093
J Neurochem. 1990 Dec;55(6):2008-14
1700071